Drug-resistant tuberculosis: Time for visionary political leadership

The Lancet Infectious Diseases

Volumn 13, Issue 6, 2013, Pages 529-539

  Abubakar, Ibrahim ^a,b   Zignol, Matteo ^c   Falzon, Dennis ^c   Raviglione, Mario ^c   Ditiu, Lucica ^d   Masham, Susan ^e,f   Adetifa, Ifedayo ^g   Ford, Nathan ^h,i   Cox, Helen ^h,i   Lawn, Stephen D ^j   Marais, Ben J ^k   McHugh, Timothy D ^a   Mwaba, Peter ^m,u   Bates, Matthew ^a,l   Lipman, Marc ^a   Zijenah, Lynn ⁿ   Logan, Simon ^e   McNerney, Ruth ^j   Zumla, Adam ^l,o   Sarda, Krishna ^p   Nahid, Payam ^q   Hoelscher, Michael ^r   Pletschette, Michel ^s   Memish, Ziad A ^u,v   Kim, Peter ^y   Hafner, Richard ^y   Cole, Stewart ^w   Migliori, Giovanni Battista ^t   Maeurer, Markus ^x   Schito, Marco ^y   Zumla, Alimuddin ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d Stop TB Partnership   (Switzerland)

^e All Party Parliamentary Group on Global Tuberculosis   (United Kingdom)

^f HOUSE OF LORDS   (United Kingdom)

^g MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^h MÉDECINS SANS FRONTIÈRES   (Switzerland)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^k UNIVERSITY OF SYDNEY   (Australia)

^l ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^m MINISTRY OF HEALTH   (Zambia)

ⁿ UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^o UNIVERSITY OF LONDON   (United Kingdom)

^p India 800 Foundation   (India)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^s UNIVERSITY OF ZURICH   (Switzerland)

^t IRCCS   (Italy)

^u MINISTRY OF HEALTH   (Saudi Arabia)

^v ALFAISAL UNIVERSITY   (Saudi Arabia)

^w EPFL   (Switzerland)

^x KAROLINSKA INSTITUTE   (Sweden)

^y NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; CLOFAZIMINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

COST EFFECTIVENESS ANALYSIS; CROSS RESISTANCE; DRUG EFFICACY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FUNDING; GROUPS BY AGE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEADERSHIP; MULTIDRUG RESISTANT TUBERCULOSIS; PANDEMIC; POLITICS; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SHORT COURSE THERAPY; SOCIAL WORK; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84878434964     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70030-6     Document Type: Review

References (98)

1. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012, 379:1902-1913.
2. Global tuberculosis report 2012 2012, WHO, World Health Organization, Geneva, Switzerland.
3. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006, 81:430-432. WHO.
4. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006, 55:301-305. Centers for Disease Control and Prevention (CDC).
5. Dara M, De Colombani P, Petrova-Benedict R, et al. Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. Eur Respir J 2012, 40:1081-1090.
6. Blumberg HM, Migliori GB, Ponomarenko O, Heldal E Tuberculosis on the move. Lancet 2010, 375:2127-2129.
7. Dheda K, Migliori GB The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. Lancet 2012, 379:773-775.
8. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012, 366:2161-2170.
9. Tuberculosis MDR-TB and XDR-TB 2011 progress report World Health Organization, (accessed Feb 15, 2013). http://www.who.int/tb/challenges/mdr/factsheet_mdr_progress_march2011.pdf.
10. Zignol M, Sismanidis C, Falzon D, Glaziou P, Dara M, Floyd K Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J 2012, published online Dec 6. 10.1183/09031936.00175812.
11. Zignol M, Van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012, 90:111-119.
12. Bhatter P, Chatterjee A, Mistry N The dragon and the tiger: realties in the control of tuberculosis. Interdiscip Perspect Infect Dis 2012, 2012:625459.
13. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012, 54:579-581.
14. Migliori GB, Centis R, D'Ambrosio L, et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease?. Clin Infect Dis 2012, 54:1379-1380.
15. " Totally drug-resistant" tuberculosis: a WHO consultation on the diagnostic definition and treatment options WHO, (accessed Nov 19, 2012). http://www.who.int/entity/tb/challenges/xdr/Report_Meeting_totallydrugresistantTB_032012.pdf.
16. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136:420-425.
17. TB India 2012. Revised national TB control programme. Annual status report Government of India, (accessed Nov 14, 2012). http://tbcindia.nic.in/pdfs/TB%20India%202012-%20Annual%20Report.pdf.
18. Roadmap to prevent and combat drug-resistant tuberculosis. The consolidated action plan to prevent and combat multidrug and extensively drug-resistant tuberculosis in the WHO European Region, 2011-2015 2011, WHO, World Health Organisation, Copenhagen, (accessed Nov 12, 2012). http://www.euro.who.int/__data/assets/pdf_file/0011/148376/RC61_InfDoc3.pdf.
19. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012, 39:1425-1431.
20. Jenkins HE, Plesca V, Ciobanu A, et al. Assessing spatial heterogeneity of MDR-TB in a high burden country. Eur Respir J (in press).
21. Abubakar I, Lipman M, Anderson C, Davies P, Zumla A Tuberculosis in the UK-time to regain control. BMJ 2011, 343:d4281.
22. French CE, Kruijshaar ME, Jones JA, Abubakar I The influence of socio-economic deprivation on tuberculosis treatment delays in England, 2000-2005. Epidemiol Infect 2009, 137:591-596.
23. Pedrazzoli D, Fulton N, Anderson L, Lalor M, Abubakar I, Zenner D Tuberculosis in the UK: 2012 report July 2012, Health Protection Agency, London, (accessed Nov 14, 2012). http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1317134916916.
24. Cooke GS, Beaton RK, Lessells RJ, et al. International spread of MDR TB from Tugela Ferry, South Africa. Emerging Infect Dis 2011, 17:2035-2037.
25. Ruddy MC, Davies AP, Yates MD, et al. Outbreak of isoniazid resistant tuberculosis in north London. Thorax 2004, 59:279-285.
26. Abubakar I, Moore J, Drobniewski F, et al. Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. Thorax 2009, 64:512-515.
27. Immigration: pre-entry screening for tuberculosis Lords Hansard Statement, (accessed Jan 18, 2013). http://www.publications.parliament.uk/.
28. Lowenthal P, Westenhouse J, Moore M, Posey DL, Watt JP, Flood J Reduced importation of tuberculosis after the implementation of an enhanced pre-immigration screening protocol. Int J Tuberc Lung Dis 2011, 15:761-766.
29. Balaji V, Daley P, Anand AA, et al. Risk factors for MDR and XDR-TB in a tertiary referral hospital in India. PLoS One 2010, 5:e9527.
30. Van der Werf MJ, Langendam MW, Huitric E, Manissero D Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 2012, 39:1511-1519.
31. Zhao P, Li XJ, Zhang SF, Wang XS, Liu CY Social behaviour risk factors for drug resistant tuberculosis in mainland China: a meta-analysis. J Int Med Res 2012, 40:436-445.
32. Van der Werf MJ, Langendam MW, Huitric E, Manissero D Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 2012, 39:1511-1519.
33. Weyer K, Mirzayev F, Migliori G, et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert(R)MTB/RIF. Eur Respir J 2012, published online Nov 22. 10.1183/09031936.00157212.
34. Marais BJ, Raviglione MC, Donald PR, et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet 2010, 375:2179-2191.
35. Cohen T, Van Helden PD, Wilson D, et al. Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clin Microbiol Rev 2012, 25:708-719.
36. Caws M, Thwaites G, Stepniewska K, et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. J Clin Microbiol 2006, 44:3934-3939.
37. Hu Y, Ma X, Graviss EA, Wang W, Jiang W, Xu B A major subgroup of Beijing family Mycobacterium tuberculosis is associated with multidrug resistance and increased transmissibility. Epidemiol Infect 2011, 139:130-138.
38. Barry PM, Gardner TJ, Funk E, et al. Multistate outbreak of MDR TB identified by genotype cluster investigation. Emerging Infect Dis 2012, 18:113-116.
39. Cohen T, Murray M, Abubakar I, et al. Multiple introductions of multidrug-resistant tuberculosis into households, Lima, Peru. Emerging Infect Dis 2011, 17:969-975.
40. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
41. Kruijshaar ME, Watson JM, Drobniewski F, et al. Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. BMJ 2008, 336:1231-1234.
42. Gavín P, Iglesias MJ, Jiménez MS, et al. Long-term molecular surveillance of multidrug-resistant tuberculosis in Spain. Infect Genet Evol 2012, 12:701-710.
43. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007, 196(suppl 1):S86-S107.
44. The Global Fund: a bleak future ahead. Lancet 2010, 376:1274. The Lancet.
45. Schaaf HS, Marais BJ Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev 2011, 12:31-38.
46. Seddon JA, Thee S, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect 2012, S0163-4453(12)00253-8 published online Sep 6. 10.1016/j.jinf.2012.09.002.
47. Seddon JA, Hesseling AC, Schaaf HS Retooling existing tuberculosis drugs for children. Clin Infect Dis 2012, 56:167-168.
48. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N Treatment outcomes of children with multi-drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:449-456.
49. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 1991, 40:585-591. Centers for Disease Control (CDC).
50. Nodieva A, Jansone I, Broka L, Pole I, Skenders G, Baumanis V Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2010, 14:427-433.
51. Farley JE, Tudor C, Mphahlele M, et al. A national infection control evaluation of drug-resistant tuberculosis hospitals in South Africa. Int J Tuberc Lung Dis 2012, 16:82-89.
52. Olson S, English RA, Guenther RS, Claiborne AB The new profile of drug-resistant tuberculosis in Russia: a global and local perspective. Summary of a joint workshop 2011, National Academies Press (US), Washington DC.
53. Olson S, English RA, Guenther RS, Claiborne AB Facing the reality of drug-resistant tuberculosis in India: challenges and potential solutions. Summary of a joint workshop by the Institute of Medicine, the Indian National Science Academy, and the Indian Council of Medical Research 2012, National Academies Press (US), Washington DC.
54. Mar 19, 2012. Tuberculosis surveillance and monitoring in Europe 2012 European Centre for Disease Prevention and Control, WHO Regional Office for EuropeWHO Regional Office for Europe, (accessed Aug 29, 2012). http://ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=841.
55. Trends in tuberculosis-United States, 2011. MMWR Morb Mortal Wkly Rep 2012, 61:181-185. Centers for Disease Control and Prevention (CDC).
56. Keshavjee S, Gelmanova IY, Pasechnikov AD, et al. Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Ann N Y Acad Sci 2008, 1136:1-11.
57. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006, 12:1389-1397.
58. Paolo WF, Nosanchuk JD Tuberculosis in New York city: recent lessons and a look ahead. Lancet Infect Dis 2004, 4:287-293.
59. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA Tuberculosis in New York City-turning the tide. N Engl J Med 1995, 333:229-233.
60. Cantwell MF, Snider DE, Cauthen GM, Onorato IM Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994, 272:535-539.
61. Hinman AR, Hughes JM, Berreth DA, et al. National action plan to combat multidrug-resistant tuberculosis. MMWR Recomm Rep 1992, 41:5-48.
62. Mitruka K, Oeltmann JE, Ijaz K, Haddad MB Tuberculosis outbreak investigations in the United States, 2002-2008. Emerging Infect Dis 2011, 17:425-431.
63. Tuberculosis outbreak associated with a homeless shelter-Kane County, Illinois, 2007-2011. MMWR Morb Mortal Wkly Rep 2012, 61:186-189. Centers for Disease Control and Prevention (CDC).
64. Veen J, Migliori GB, Raviglione M, et al. Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops. Eur Respir J 2011, 37:950-959.
65. Blöndal K, Viiklepp P, Blöndal P, Altraja A Countrywide management of pulmonary tuberculosis reverses increasing incidence. Int J Tuberc Lung Dis 2011, 15:892-898.
66. Guidelines for the programmatic management of drug resistant tuberculosis. 2011 update WHO, (accessed Oct 18, 2012). http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf.
67. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
68. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9:e1001300.
69. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2012, published online Oct 25. 10.1183/09031936.00134712.
70. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009, 4:e6914.
71. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161.
72. Tocsec A, Cox H, Du Cross P, Cooke G, Fox N Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013, 17:299-307.
73. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur Respir J 2012, published online Oct 11. 10.1183/09031936.00136312.
74. Keshavjee S, Farmer PE Picking up the pace-scale-up of MDR tuberculosis treatment programs. N Engl J Med 2010, 363:1781-1784.
75. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerging Infect Dis 2006, 12:1389-1397.
76. Van Deun A, Maug AKJ, Salim MAH, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182:684-692.
77. Spigelman M, Woosley R, Gheuens J New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis 2010, 14:663-664.
78. Voelker R MDR-TB has new drug foe after fast-track approval. JAMA 2013, 309:430.
79. Nunn A What is the role of clinical trials for the treatment of tuberculosis and what are the alternatives?. Int J Tuberc Lung Dis 2010, 14:380-381.
80. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360:2397-2405.
81. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur Respir J 2012, published online Sept 27. 10.1183/09031936.00125812.
82. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012, 380:986-993.
83. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem/clavunate added to linezolid containing regimens in the treatment of M/XDR-TB. Eur Respir J 2012, published online Sept 20. 10.1183/09031936.00124312.
84. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012, 40:1430-1442.
85. Alsaad N, Van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis. Eur Respir J 2012, published online Oct 25. 10.1183/09031936.00114812.
86. Amaral L, Udwadia Z, Abbate E, Van Soolingen D The added effect of thioridazine in the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012, 16:1706-1708.
87. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004, 38:1538-1544.
88. Törün T, Güngör G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005, 9:1373-1377.
89. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010, 14:275-281.
90. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007, 4:e292.
91. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
92. Towards universal access to diagnosis and treatmnent of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO Progress Report 2011 2011, WHO, World Health Organization, Geneva.
93. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis-critical steps for prevention and control. N Engl J Med 2010, 363:1050-1058.
94. Raviglione MC, Lange C, Migliori GB Preventing and managing antimicrobial resistance: imperative for chest physicians. Eur Respir J 2011, 37:978-981.
95. Migliori GB, Langendam MW, D'Ambrosio L, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 2012, 40:814-822.
96. Sotgiu G, D'Ambrosio L, Centis R, et al. TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?. Eur Respir J 2011, 38:1221-1223.
97. Abubakar I, Dara M, Manissero D, Zumla A Tackling the spread of drug-resistant tuberculosis in Europe. Lancet 2012, 379:21-23.
98. Keshavjee S, Farmer PE Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 2012, 367:931-936.